[{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C||Protein kinase C delta type; Protein kinase C alpha type","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Center for Clinical Studies, Texas","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C||Protein kinase C delta type; Protein kinase C alpha type","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Center for Clinical Studies, Texas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Center for Clinical Studies, Texas \/ Leo Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Center for Clinical Studies, Texas \/ Leo Pharma"},{"orgOrder":0,"company":"Korea University","sponsor":"Leo Pharma | Chonnam National University Hospital | Severance Hospital | Ajou University School of Medicine | Asan Medical Center | Samsung Medical Center | Seoul National University Bundang Hospital | Dong-A University Hospital | Korea University Anam Ho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Korea University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Korea University \/ Leo Pharma | Chonnam National University Hospital | Severance Hospital | Ajou University School of Medicine | Asan Medical Center | Samsung Medical Center | Seoul National University Bundang Hospital | Dong-A University Hospital | Korea University Anam Ho","highestDevelopmentStatusID":"11","companyTruncated":"Korea University \/ Leo Pharma | Chonnam National University Hospital | Severance Hospital | Ajou University School of Medicine | Asan Medical Center | Samsung Medical Center | Seoul National University Bundang Hospital | Dong-A University Hospital | Korea University Anam Ho"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Peplin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase II","graph3":"Peplin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Peplin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Peplin \/ Undisclosed"},{"orgOrder":0,"company":"Peplin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Undisclosed","graph2":"Phase II","graph3":"Peplin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Peplin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Peplin \/ Undisclosed"},{"orgOrder":0,"company":"Peplin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Oncology","graph2":"Phase II","graph3":"Peplin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Peplin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Peplin \/ Undisclosed"},{"orgOrder":0,"company":"Pacific Dermaesthetics","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase II","graph3":"Pacific Dermaesthetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pacific Dermaesthetics \/ Leo Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Pacific Dermaesthetics \/ Leo Pharma"},{"orgOrder":0,"company":"Skin Laser & Surgery Specialists","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Skin Laser & Surgery Specialists","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Skin Laser & Surgery Specialists \/ Leo Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Skin Laser & Surgery Specialists \/ Leo Pharma"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Leo Pharma"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Leo Pharma"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Leo Pharma"},{"orgOrder":0,"company":"University of Sao Paulo","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Undisclosed","graph3":"University of Sao Paulo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"University of Sao Paulo \/ Leo Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University of Sao Paulo \/ Leo Pharma"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Leo Pharma"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Goldman, Butterwick, Fitzpatrick and Groff","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Goldman, Butterwick, Fitzpatrick and Groff"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Neal D. Bhatia, MD","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Neal D. Bhatia, MD","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Neal D. Bhatia, MD"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Merete Haedersdal","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Merete Haedersdal","highestDevelopmentStatusID":"7","companyTruncated":"Leo Pharma \/ Merete Haedersdal"}]
Find Clinical Drug Pipeline Developments & Deals for Ingenol Mebutate
Details :
Ingenol Mebutate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Basal Cell.
Details :
Picato (Ingenol Mebutate) is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Keratosis, Actinic.
Details :
Picato is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Molluscum Contagiosum.
Details :
Ingenol Mebutate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Keratosis, Actinic.
Details :
Ingenol Mebutate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Warts.
Sponsor :
Leo Pharma | Chonnam National University Hospital | Severance Hospital | Ajou University School of Medicine | Asan Medical Center | Samsung Medical Center | Seoul National University Bundang Hospital | Dong-A University Hospital | Korea University Anam Ho
Details :
Ingenol Mebutate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Keratosis, Actinic.
Sponsor :
Leo Pharma | Chonnam National University Hospital | Severance Hospital | Ajou University School of Medicine | Asan Medical Center | Samsung Medical Center | Seoul National University Bundang Hospital | Dong-A University Hospital | Korea University Anam Ho
Details :
Ingenol Mebutate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Keratosis, Actinic.
Details :
Ingenol Mebutate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Keratosis, Actinic.
Details :
Ingenol Mebutate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Keratosis, Actinic.
Details :
Ingenol Mebutate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Keratosis, Actinic.
Reset All
